Results 151 to 160 of about 8,768 (188)
Some of the next articles are maybe not open access.
Thinking of bosentan repurposing – A study on dehydration and amorphization [PDF]
International Journal of Pharmaceutics, 2022 International audienceNew clinical indications for an orphan drug bosentan are prompting the improvement of the drug formulation. Since bosentan is available as monohydrate, the information on its anhydrous form together with the assessment of its glass ...
Anna Krupa +2 more
exaly +2 more sources
Down patients with Eisenmenger syndrome: Is bosentan treatment an option? [PDF]
International Journal of Cardiology, 2009 Contains fulltext : 80912.pdf (Publisher’s version ) (Open Access)BACKGROUND: Favorable results of treatment with bosentan in patients with Eisenmenger syndrome are available. However, data in Down patients are lacking.
Jeroen C Vis +2 more
exaly +2 more sources
Expert Review of Cardiovascular Therapy, 2004
Bosentan (Tracleer, Actelion Pharmaceuticals Ltd) is an oral dual endothelin receptor antagonist approved for use in functional class III to IV pulmonary arterial hypertension. In two placebo-controlled trials, patients receiving bosentan showed improved functional class, 6-minute walk distance and hemodynamics over a 12- to 16-week period.
Kelly, Chin, Richard, Channick
openaire +3 more sources
Bosentan (Tracleer, Actelion Pharmaceuticals Ltd) is an oral dual endothelin receptor antagonist approved for use in functional class III to IV pulmonary arterial hypertension. In two placebo-controlled trials, patients receiving bosentan showed improved functional class, 6-minute walk distance and hemodynamics over a 12- to 16-week period.
Kelly, Chin, Richard, Channick
openaire +3 more sources
Expert Opinion on Pharmacotherapy, 2010
Pulmonary arterial hypertension (PAH) is a morbid condition with high mortality if left untreated. Bosentan is an effective treatment option for group 1 pulmonary arterial hypertension. Bosentan improves exercise tolerance and functional class and delays the time to clinical worsening in these patients.
Michael A, Mathier, David, Ishizawar
openaire +3 more sources
Pulmonary arterial hypertension (PAH) is a morbid condition with high mortality if left untreated. Bosentan is an effective treatment option for group 1 pulmonary arterial hypertension. Bosentan improves exercise tolerance and functional class and delays the time to clinical worsening in these patients.
Michael A, Mathier, David, Ishizawar
openaire +3 more sources
American Journal of Cardiovascular Drugs, 2002
Bosentan is a nonpeptide, specific, competitive, dual antagonist at both endothelin receptor subtypes (ET(A) and ET(B)). Orally administered bosentan effectively prevents endothelin 1-induced vasoconstriction in pulmonary vessels in patients with pulmonary arterial hypertension.
Amitabh, Prakash, Caroline M, Perry
openaire +3 more sources
Bosentan is a nonpeptide, specific, competitive, dual antagonist at both endothelin receptor subtypes (ET(A) and ET(B)). Orally administered bosentan effectively prevents endothelin 1-induced vasoconstriction in pulmonary vessels in patients with pulmonary arterial hypertension.
Amitabh, Prakash, Caroline M, Perry
openaire +3 more sources
Expert Opinion on Investigational Drugs, 1998
This article describes the pharmacological properties and the overall preclinical and clinical profiling of bosentan (Ro 47-0203), a non-peptide endothelin receptor antagonist with oral activity. Bosentan is a combined and competitive antagonist of both ETA and ETB receptors that is selective for the endothelin system.
V, Breu, S I, Ertel, S, Roux, M, Clozel
openaire +2 more sources
This article describes the pharmacological properties and the overall preclinical and clinical profiling of bosentan (Ro 47-0203), a non-peptide endothelin receptor antagonist with oral activity. Bosentan is a combined and competitive antagonist of both ETA and ETB receptors that is selective for the endothelin system.
V, Breu, S I, Ertel, S, Roux, M, Clozel
openaire +2 more sources
Heart Disease, 2003
Bosentan is the first endothelin (ET) receptor antagonist approved by the Food and Drug Administration for the management of pulmonary arterial hypertension (PAH). In patients with World Health Organization Class III and IV PAH, bosentan has demonstrated improvement in dyspnea and exercise tolerance.
openaire +2 more sources
Bosentan is the first endothelin (ET) receptor antagonist approved by the Food and Drug Administration for the management of pulmonary arterial hypertension (PAH). In patients with World Health Organization Class III and IV PAH, bosentan has demonstrated improvement in dyspnea and exercise tolerance.
openaire +2 more sources